佳礼资讯网

 找回密码
 注册

ADVERTISEMENT

楼主: 北乔峰

【DPHARMA 7148 交流专区】(前名 CCMDBIO)

  [复制链接]
发表于 22-4-2012 10:45 PM | 显示全部楼层
最近好像感冒咳嗽肆虐马来西亚和新加坡。
走到那里都看到生病的人。
而周围的人好像都生病。。。
药剂业是不是会有好消息呢??
回复

使用道具 举报


ADVERTISEMENT

发表于 18-5-2012 01:14 AM | 显示全部楼层

SUMMARY OF KEY FINANCIAL INFORMATION

31/03/2012



INDIVIDUAL PERIOD

CUMULATIVE PERIOD

CURRENT YEAR QUARTER

PRECEDING YEAR
CORRESPONDING
QUARTER

CURRENT YEAR TO DATE

PRECEDING YEAR
CORRESPONDING
PERIOD

31/03/2012

31/03/2011

31/03/2012

31/03/2011

$$'000

$$'000

$$'000

$$'000

1Revenue

36,057

32,984

36,057

32,984

2Profit/(loss) before tax

8,869

7,875

8,869

7,875

3Profit/(loss) for the period

6,708

5,924

6,708

5,924

4Profit/(loss) attributable to ordinary equity holders of the parent

6,708

5,924

6,708

5,924

5Basic earnings/(loss) per share (Subunit)

4.83

4.27

4.83

4.27

6Proposed/Declared dividend per share (Subunit)

0.00

0.00

0.00

0.00









AS AT END OF CURRENT QUARTER

AS AT PRECEDING FINANCIAL YEAR END

7
Net assets per share attributable to ordinary equity holders of the parent ($$)

1.2300

1.1800

回复

使用道具 举报

发表于 12-7-2012 07:27 PM | 显示全部楼层
CENTURY BOND BHD
12/07/2012 05:14:06 PM
TypeAnnouncement
SubjectOTHERS
DescriptionPROPOSED FINAL TAX-EXEMPT DIVIDEND OF 2.5 SEN PER SHARE IN RESPECT OF THE FINANCIAL YEAR ENDED 31 MARCH 2012
Century Bond Bhd is pleased to announce that the Board of Directors proposes a final tax-exempt dividend of 2.5 sen per share in respect of the financial year ended 31 March 2012 which is subject to shareholders' approval at the forthcoming 20th Annual General Meeting.
The entitlement date and payment date for the proposed final dividend will be determined at a later date.
回复

使用道具 举报

发表于 16-8-2012 08:29 PM | 显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30/06/2012
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
30/06/2012
30/06/2011
30/06/2012
30/06/2011
$$'000
$$'000
$$'000
$$'000
1Revenue
34,355
35,345
70,412
68,329
2Profit/(loss) before tax
9,037
9,292
17,906
17,166
3Profit/(loss) for the period
6,867
6,932
13,575
12,856
4Profit/(loss) attributable to ordinary equity holders of the parent
6,867
6,932
13,575
12,856
5Basic earnings/(loss) per share (Subunit)
4.95
4.99
9.78
9.26
6Proposed/Declared dividend per share (Subunit)
3.50
3.50
3.50
3.50


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
1.1700
1.1800

回复

使用道具 举报

发表于 16-8-2012 08:29 PM | 显示全部楼层
CCM DUOPHARMA BIOTECH BERHAD
16/08/2012 05:03:05 PM
EX-date
15/10/2012
Entitlement date
17/10/2012
Entitlement time
04:00:00 PM
Entitlement subject
Interim Dividend
Entitlement description
Interim Tax-Exempt Dividend of 3.5 sen per ordinary share of RM0.50 each for the financial year ending 31 December 2012.
Period of interest payment
to
Financial Year End
31/12/2012
Share transfer book & register of members will be
to closed from (both dates inclusive) for the purpose of determining the entitlements
Registrar's name ,address, telephone no
Tricor Investor Services Sdn Bhd
Level 17, The Gardens North Tower
Mid Valley City, Lingkaran Syed Putra
59200 Kuala Lumpur

Telephone No.: 03-2264 3883
Facsimile No.: 03-2282 1886
Payment date
09/11/2012
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers
17/10/2012
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit

c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)

Entitlement indicator
Currency
Currency
Malaysian Ringgit (MYR)
Entitlement in Currency
0.035

回复

使用道具 举报

发表于 23-11-2012 09:46 PM | 显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30/09/2012
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
30/09/2012
30/09/2011
30/09/2012
30/09/2011
$$'000
$$'000
$$'000
$$'000
1Revenue
29,521
36,767
99,932
105,096
2Profit/(loss) before tax
8,392
9,726
26,298
26,892
3Profit/(loss) for the period
6,442
7,521
20,017
20,377
4Profit/(loss) attributable to ordinary equity holders of the parent
6,442
7,521
20,017
20,377
5Basic earnings/(loss) per share (Subunit)
4.64
5.42
14.42
14.68
6Proposed/Declared dividend per share (Subunit)
0.00
0.00
0.00
0.00


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
1.2100
1.1800

回复

使用道具 举报

Follow Us
发表于 26-2-2013 12:41 AM | 显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
31/12/2012
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
31/12/2012
31/12/2011
31/12/2012
31/12/2011
$$'000
$$'000
$$'000
$$'000
1Revenue
35,378
33,036
135,310
138,132
2Profit/(loss) before tax
9,000
7,836
35,298
34,728
3Profit/(loss) for the period
5,997
6,329
26,014
26,705
4Profit/(loss) attributable to ordinary equity holders of the parent
5,997
6,329
26,014
26,705
5Basic earnings/(loss) per share (Subunit)
4.32
4.56
18.74
19.24
6Proposed/Declared dividend per share (Subunit)
10.50
9.70
14.00
11.26


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
1.2200
1.1800

回复

使用道具 举报

发表于 23-3-2013 03:31 PM | 显示全部楼层
CCM DUOPHARMA BIOTECH BERHAD

EX-date
14/06/2013
Entitlement date
18/06/2013
Entitlement time
04:00:00 PM
Entitlement subject
Final Dividend
Entitlement description
Final dividend of 10.5 sen per ordinary share, tax exempt under the single-tier tax system
Period of interest payment
to
Financial Year End
31/12/2012
Share transfer book & register of members will be
to closed from (both dates inclusive) for the purpose of determining the entitlements
Registrar's name ,address, telephone no
Tricor Investor Services Sdn Bhd
Level 17, The Gardens North Tower
Mid Valley City, Lingkaran Syed Putra
59200 Kuala Lumpur
Telephone no: 03-2264 3883
Payment date
12/07/2013
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers
18/06/2013
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit

c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)

Entitlement indicator
Currency
Currency
Malaysian Ringgit (MYR)
Entitlement in Currency
0.105

Remarks :
The Final Dividend is subject to shareholders' approval at the forthcoming Annual General Meeting.


回复

使用道具 举报


ADVERTISEMENT

发表于 28-5-2013 02:31 AM | 显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
31/03/2013
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
31/03/2013
31/03/2012
31/03/2013
31/03/2012
$$'000
$$'000
$$'000
$$'000
1Revenue
37,837
36,057
37,837
36,057
2Profit/(loss) before tax
8,956
8,869
8,956
8,869
3Profit/(loss) for the period
6,699
6,708
6,699
6,708
4Profit/(loss) attributable to ordinary equity holders of the parent
6,699
6,708
6,699
6,708
5Basic earnings/(loss) per share (Subunit)
4.83
4.83
4.83
4.83
6Proposed/Declared dividend per share (Subunit)
0.00
0.00
0.00
0.00


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
1.2700
1.2200

回复

使用道具 举报

发表于 14-6-2013 03:11 PM | 显示全部楼层
馬化學藥業將聯營併購

大馬  2013-06-14 10:34
(吉隆坡13日訊)馬化學藥業(CCMDBIO,7148,主板消費品組)首席執行員李奧納阿里夫說,馬化學藥業將積極開拓東盟市場,並放眼海外市場取得雙位數業務成長。

他指出,基於東盟各國對藥業法規的鬆緊各異,為了克服進軍區域市場的各項障礙,決定透過聯營(持有多數股)、併購方式擴展業務。

他今日在股東大會上後指出,海外市場只佔營業額的很小比重,因而成長空間非常大,藉此擴展有望取得較上財政年更佳業績。

看中印菲越人口龐大

公司首席財務員祝武光披露,海外市場約佔營業額8%,或2013年營業額的8%,或相等於1千100萬令吉。

李奧納說,未來將專注開發印尼、菲律賓與越南市場,主要是其人口龐大,也考慮進軍中東,不過中東市場還在起步階段。

他說,公司藥業產品出口市場主要在新加坡與泰國,新加坡藥業法規環境幾乎與大馬相同,因而容易進入市場,泰國的也還順利,全球總共出口至20多個國家。

他指出,印尼市場目前也已委任一名國家主管派駐印尼,越南則設有代辦事處及委任經銷商。

他說,藥業的營運環境非常具競爭性,有時也面臨各國的保護主義,目前主要面臨中國、印度、巴基斯坦等學名藥的競爭,因而必須加強國際競爭力,長遠才能生存。

“為確保有足夠競爭力,每年也撥出營業額的2%,作為研發用途。”

他說,除此,公司未來的其餘兩項策略,還包括與跨國公司探討腫瘤臨床療效和為腎衰竭病人展開紅血球生成素(EPO)臨床實驗、在清真藥劑居領導地位。

該公司去年在美國波斯頓舉行的生物國際大會上,與韓國公司Pangen Biotech公司簽署協議,以對末期腎衰竭病人展開類似臨床實驗。

另外,他指出,在腫瘤臨床療效與跨國公司合作,主要是配合政府鼓勵更多合伙計劃的意願,以開發這方面的無限潛能,他也相信這只是其生產仿製業的一個起步。

全球生物仿製業市場在2011年上半年的市值達3億7千800萬美元(約11億7千200萬令吉),預料可在2015年增至19億至26億美元(約58億9千萬至80億6千萬令吉)。(星洲日報/財經)
回复

使用道具 举报

发表于 5-8-2013 04:54 PM | 显示全部楼层
回复

使用道具 举报

发表于 29-8-2013 02:40 AM | 显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30/06/2013
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
30/06/2013
30/06/2012
30/06/2013
30/06/2012
$$'000
$$'000
$$'000
$$'000
1Revenue
37,988
34,355
75,826
70,412
2Profit/(loss) before tax
13,007
9,037
21,963
17,906
3Profit/(loss) for the period
10,689
6,867
17,388
13,575
4Profit/(loss) attributable to ordinary equity holders of the parent
10,689
6,867
17,388
13,575
5Basic earnings/(loss) per share (Subunit)
7.70
4.95
12.53
9.78
6Proposed/Declared dividend per share (Subunit)
4.00
3.50
4.00
3.50


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
1.3500
1.2200

回复

使用道具 举报

发表于 29-8-2013 02:41 AM | 显示全部楼层
CCM DUOPHARMA BIOTECH BERHAD

EX-date
14/10/2013
Entitlement date
17/10/2013
Entitlement time
04:00:00 PM
Entitlement subject
Interim Dividend
Entitlement description
Interim Single Tier Dividend of 4 sen per ordinary share
Period of interest payment
to
Financial Year End
31/12/2013
Share transfer book & register of members will be
to closed from (both dates inclusive) for the purpose of determining the entitlements
Registrar's name ,address, telephone no
Tricor Investor Services Sdn Bhd
Level 17, The Gardens North Tower
Mid Valley City, Lingkaran Syed Putra
59200 Kuala Lumpur
Telephone no.: 03-2264 3883
Payment date
08/11/2013
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers
17/10/2013
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit

c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)

Entitlement indicator
Currency
Currency
Malaysian Ringgit (MYR)
Entitlement in Currency
0.04

回复

使用道具 举报

发表于 29-8-2013 10:49 AM | 显示全部楼层
回复

使用道具 举报

发表于 20-11-2013 10:51 PM | 显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30/09/2013
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
30/09/2013
30/09/2012
30/09/2013
30/09/2012
$$'000
$$'000
$$'000
$$'000
1Revenue
40,845
29,521
116,671
99,932
2Profit/(loss) before tax
9,054
8,391
31,017
26,298
3Profit/(loss) for the period
6,786
6,442
24,175
20,017
4Profit/(loss) attributable to ordinary equity holders of the parent
6,786
6,442
24,175
20,017
5Basic earnings/(loss) per share (Subunit)
4.89
4.64
17.41
14.42
6Proposed/Declared dividend per share (Subunit)
0.00
0.00
0.00
0.00


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
1.2900
1.2200

回复

使用道具 举报

发表于 27-2-2014 03:37 AM | 显示全部楼层
馬化工聯藥 淨利漲55%

企業財經26 Feb 2014 23:00
(吉隆坡26日訊)私人醫院和政府醫院業務收入推動,馬化工聯藥(CCMDBIO,7148,主要板消費)上財年截至12月底末季,營業額按年上漲29%至4573萬令吉,淨利大漲55%至931萬令吉,每股派息13.5仙。

該公司全年營業額按年增長20%至1億6241萬令吉,淨利揚14%至3228萬令吉,全年股息17.5仙。

馬化工聯藥指出,公司的私人醫院和政府醫院業務收入增長顯著,推動公司營業額成長,但稅前盈利未隨營業額漲幅增加。

儘管未來全球經濟不穩定,但該公司預計醫療行業依然能穩健成長。【中国报财经】

SUMMARY OF KEY FINANCIAL INFORMATION
31/12/2013
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
31/12/2013
31/12/2012
31/12/2013
31/12/2012
$$'000
$$'000
$$'000
$$'000
1Revenue
45,734
35,378
162,405
135,310
2Profit/(loss) before tax
9,160
9,000
40,175
35,298
3Profit/(loss) for the period
9,313
5,998
32,275
26,014
4Profit/(loss) attributable to ordinary equity holders of the parent
9,313
5,998
32,275
26,014
5Basic earnings/(loss) per share (Subunit)
6.71
4.32
23.25
18.74
6Proposed/Declared dividend per share (Subunit)
13.50
10.50
17.50
14.00


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
1.3100
1.2200

本帖最后由 icy97 于 27-2-2014 11:03 PM 编辑

回复

使用道具 举报


ADVERTISEMENT

发表于 27-2-2014 11:04 PM | 显示全部楼层
CCM DUOPHARMA BIOTECH BERHAD

EX-date
22/05/2014
Entitlement date
26/05/2014
Entitlement time
04:00:00 PM
Entitlement subject
Final Dividend
Entitlement description
Final Dividend of 13.5 sen per ordinary share, tax exempt dividend under the single-tier system
Period of interest payment
to
Financial Year End

Share transfer book & register of members will be
to closed from (both dates inclusive) for the purpose of determining the entitlements
Registrar's name ,address, telephone no
Tricor Investor Services Sdn Bhd
Level 17, The Gardens North Tower
Mid Valley City, Lingkaran Syed Putra
59200 Kuala Lumpur
Telephone no.: 03-2264 3883
Payment date
20/06/2014
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers
26/05/2014
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit

c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)

Entitlement indicator
Currency
Currency
Malaysian Ringgit (MYR)
Entitlement in Currency
0.135

回复

使用道具 举报

发表于 21-5-2014 04:24 AM | 显示全部楼层
马化工药业净利增25%

财经新闻 财经  2014-05-21 12:20
(吉隆坡20日讯)马化工药业(CCMDBIO,7148,主板消费产品股)截至3月杪首季净利年增25%,至836万5000令吉,相等于每股盈利6.03仙。

上财年同期净利为669万9000令吉。

首季营业额则按年增长7%至4049万5000令吉,上财年同期为3783万7000令吉。

另一方面,马化工药业总执行长伦纳德阿立夫在股东大会后向媒体表示,放眼每年推出5项新产品,以巩固业绩增长策略。

目前,公司每年推出2项新产品。【南洋网财经】

SUMMARY OF KEY FINANCIAL INFORMATION
31/03/2014
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
31/03/2014
31/03/2013
31/03/2014
31/03/2013
$$'000
$$'000
$$'000
$$'000
1Revenue
40,495
37,837
40,495
37,837
2Profit/(loss) before tax
11,175
8,956
11,175
8,956
3Profit/(loss) for the period
8,365
6,699
8,365
6,699
4Profit/(loss) attributable to ordinary equity holders of the parent
8,365
6,699
8,365
6,699
5Basic earnings/(loss) per share (Subunit)
6.03
4.83
6.03
4.83
6Proposed/Declared dividend per share (Subunit)
0.00
0.00
0.00
0.00


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
1.3700
1.3100

本帖最后由 icy97 于 22-5-2014 02:01 AM 编辑

回复

使用道具 举报

发表于 27-8-2014 06:17 AM | 显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30/06/2014
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
30/06/2014
30/06/2013
30/06/2014
30/06/2013
$$'000
$$'000
$$'000
$$'00
1Revenue
40,623
37,988
81,118
75,826
2Profit/(loss) before tax
10,107
13,007
21,302
21,963
3Profit/(loss) for the period
7,513
10,689
15,892
17,388
4Profit/(loss) attributable to ordinary equity holders of the parent
7,513
10,689
15,892
17,388
5Basic earnings/(loss) per share (Subunit)
5.41
7.70
11.45
12.53
6Proposed/Declared dividend per share (Subunit)
4.00
4.00
4.00
4.00


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
1.2900
1.3100

回复

使用道具 举报

发表于 27-8-2014 06:17 AM | 显示全部楼层
EX-date
15/10/2014
Entitlement date
17/10/2014
Entitlement time
04:00:00 PM
Entitlement subject
Interim Dividend
Entitlement description
Interim Single Tier Dividend of 4 sen per ordinary share
Period of interest payment
to
Financial Year End
31/12/2014
Share transfer book & register of members will be
to closed from (both dates inclusive) for the purpose of determining the entitlements
Registrar's name ,address, telephone no
Tricor Investor Services Sdn Bhd
Level17, The Gardens North Tower
Mid Valley City, Lingkaran Syed Putra
59200 Kuala Lumpur
Telephone no.: 03-2264 3883
Payment date
07/11/2014
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers
17/10/2014
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit

c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)

Entitlement indicator
Currency
Currency
Malaysian Ringgit (MYR)
Entitlement in Currency
0.04

回复

使用道具 举报

您需要登录后才可以回帖 登录 | 注册

本版积分规则

 

ADVERTISEMENT



ADVERTISEMENT



ADVERTISEMENT

ADVERTISEMENT


版权所有 © 1996-2023 Cari Internet Sdn Bhd (483575-W)|IPSERVERONE 提供云主机|广告刊登|关于我们|私隐权|免控|投诉|联络|脸书|佳礼资讯网

GMT+8, 16-4-2024 06:17 PM , Processed in 0.072353 second(s), 19 queries , Gzip On.

Powered by Discuz! X3.4

Copyright © 2001-2021, Tencent Cloud.

快速回复 返回顶部 返回列表